Could parsley and rosemary ease endometriosis pain?
NCT ID NCT07228975
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a dietary supplement made from parsley, rosemary, selenium, and vitamins in 36 women with endometriosis. The goal was to see if it could reduce pain and the need for NSAIDs. The supplement was taken daily for a period, and pain levels were measured using a standard scale.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dietary supplement containing parsley extract, rosemary extract, selenium, mountain celery, and vitamins B6, D, and E
- What this could lead to
- If it works, this could offer a natural option to help manage endometriosis pain and reduce reliance on painkillers.
- What could go wrong
- This is a very small pilot study with only 36 participants and no placebo group, so results may not be reliable or apply to everyone. Dietary supplements are not strictly regulated like drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
36 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for the Initial Run-In Phase 1. Written informed consent, signed and dated personally by the patient. 2. Female between the ages of 18 and 45 (including limits), with no race limitation. 3. Documented endometriosis, confirmed by laparoscopy, ultrasound, or MRI, with or without biopsy, performed up to 36 months prior to the start of this investigation and independently of it. 4. Stable health condition and stable drug treatments within the past 2 months. 5. Endometriosis with a grade 2 (mild) to grade 4 (severe) AFSr score, whether or not treated with sex hormones, contraceptives, or any other specific treatment, stable for a minimum of 2 months. Note: In a first phase of the investigation, patients in class 2 and 3 will be recruited, while in a second phase, patients in class 4 will also be recruited. 6. 10-point Visual Analogue Scale (VAS) score of pain due to endometriosis of at least 4 for at least 2 days in the 4 weeks prior to run-in. Inclusion criteria for treatment initiation Patients will start treatment with EndOK Green if they meet all of the following criteria. 1. Negative urine pregnancy test. 2. Difference, for at least two days, of no more than 10 in the 10-point Visual Analogue Scale (VAS) (10%) between the 4 weeks prior to the screening visit and the end of the run-in phase, provided that at least one menstruation occurred in the period. 3. No change in background therapy. Exclusion Criteria Patients will be excluded if they meet even one of the following criteria: 1. Pregnancy, breastfeeding, or intending to become pregnant during the time this investigation will be conducted. 2. Absence of cycles for at least 3 months. 3. Previous hysterectomy or oophorectomy. 4. Pelvic inflammatory disease regardless of its etiology (Chlamydia Trachomatis, Neisseria gonorrhoeae, fungi, etc.) or presence of ovarian cysts. 5. Known hypersensitivity or allergy to the active substances and/or any component of the product under investigation. 6. Patient who has taken, within 4 weeks prior to inclusion, or is currently taking, dietary supplements for the treatment of pelvic pain or other symptoms of endometriosis. 7. Participation in any clinical study that has been ongoing or concluded for less than three months. 8. Patient with one or more psychiatric disorders, such as alcoholism, substance abuse or addictive disorder, bipolar disorder, schizophrenia, or other personality disorders. 9. Patient who, in the opinion of the gynecologist, will not be able to meet the prerequisites required for this investigation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometriosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site#1 - Via Europa, 67
Alzano Lombardo, BG, 24022, Italy
-
Site#2 - Borgo Sant'Agnese, 93
Portogruaro, VE, 30026, Italy
-
Site#3 - Via Enrico De Nicola, 171
Camaiore, LU, 55041, Italy
-
Site#4 - Via Nicola Tridente, 35
Bari, BA, 70125, Italy
-
Site#5 - Via Sabbionera, 45
Latisana, UD, 33053, Italy
-
Site#6 - Capo di piazza Gianni Bartoli, 1
Trieste, TS, 34100, Italy
-
Site#7 - Via S.Maria del Pozzo, 106
Somma Vesuviana, 80049, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery pelvic floor therapy stop endometriosis pain after the operation?
- Appendix: the hidden driver of endometriosis pain?
- Allergy pill put to the test against endometriosis pain
- Can ultrasound and tissue clues reveal which endometriosis lesions carry cancer risk?
- Can AI personalize exercise to ease pelvic pain?
- Can AI learn to spot endometriosis and fibroids on ultrasound?